Previous close | 37.48 |
Open | 37.63 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 37.63 - 38.69 |
52-week range | 26.53 - 42.51 |
Volume | |
Avg. volume | 1,238 |
Market cap | 92.457M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | 0.23 |
EPS (TTM) | 1.68 |
Earnings date | 02 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
After losing some value lately, a hammer chart pattern has been formed for Dentsply (XRAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA Inc.'s ( NASDAQ:XRAY ) price-to-sales (or "P/S") ratio of 2x might make it look like a buy right now...
The heavy selling pressure might have exhausted for Dentsply (XRAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ), is not the largest company out there, but it led the NASDAQGS gainers with a...
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
Key Insights DENTSPLY SIRONA's estimated fair value is US$45.20 based on 2 Stage Free Cash Flow to Equity DENTSPLY...
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see DENTSPLY...
DENTSPLY SIRONA ( NASDAQ:XRAY ) Full Year 2022 Results Key Financial Results Revenue: US$3.92b (down 7.3% from FY...
DENTSPLY SIRONA's (XRAY) Q4 earnings and revenues decline year over year due to unfavorable foreign currency movement and soft demand across all geographical segments.
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) shareholders should be happy to see the share price up 19% in the last quarter...
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.
The orthodontic treatment market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022.
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.